加味补阳还五汤联合西药治疗特发性膜性肾病患者的效果

doi:10.3760/cma.j.cn441417-20240624-04010

摘要/Abstract

摘要：

目的　探讨加味补阳还五汤联合西药治疗特发性膜性肾病患者的效果。方法　选取2020年9月至2023年9月榆林市中医医院收治的120例特发性膜性肾病患者进行随机对照试验。采用随机数字表法将其分为对照组和观察组，各60例。对照组男42例，女18例，年龄（49.68±5.62）岁。观察组男44例，女16例，年龄（49.81±5.54）岁。对照组予以他克莫司治疗，观察组予以加味补阳还五汤联合他克莫司治疗。两组均治疗6个月。比较两组临床疗效，治疗前后脂代谢水平［总胆固醇（total cholesterol，TC）、三酰甘油（triglycerides，TG）、低密度脂蛋白（low-density lipoprotein，LDL）］、肾功能［24 h尿蛋白定量（24-hour urinary total protein，24 h-UTP）、血肌酐（serum creatinine，Scr）、尿素氮（blood urea nitrogen，BUN）］、炎症因子［转化生长因子-β1（transforming growth factor-β1，TGF-β1）、人足细胞标志蛋白（podocyte protein，PCX）、胱抑素C（cystatin C，CysC）］、凝血纤溶功能［组织型纤溶酶原激活物（tissue plasminogen activator，t-PA）、Ⅰ型纤溶酶原激活物抑制因子（type Ⅰ plasminogen activator inhibitor，PAI-Ⅰ）］，不良反应发生情况。采用χ²检验、t检验进行统计分析。结果　观察组治疗总有效率高于对照组［95.00%（57/60）比80.00%（48/60）］，差异有统计学意义（χ²=6.171，P<0.05）。治疗后，观察组TC、TG、LDL水平均低于对照组［（4.31±0.96）mmol/L比（6.39±1.24）mmol/L、（1.61±0.46）mmol/L比（2.49±0.72）mmol/L、（1.23±0.24）mmol/L比（2.59±0.41）mmol/L］，差异均有统计学意义（t=10.274、7.978、22.174，均P<0.05）。治疗后，观察组24 h-UTP、Scr、BUN水平均低于对照组［（0.56±0.24）g比（1.34±0.37）g、（82.57±7.16）μmol/L比（88.49±8.64）μmol/L、（6.02±1.03）mmol/L比（7.34±1.28）mmol/L］，差异均有统计学意义（t=13.700、4.087、6.223，均P<0.05）。治疗后，观察组TGF-β1、PCX、CysC水平均低于对照组［（235.25±14.76）ng/L比（301.59±17.64）ng/L、（7.11±1.42）μg/L比（12.24±1.78）μg/L、（0.82±0.22）mg/L比（1.18±0.34）mg/L］，差异均有统计学意义（t=22.341、17.451、6.886，P<0.05）。治疗后，观察组t-PA水平高于对照组［（6.88±1.07）μg/L比（5.42±0.97）μg/L］，PAI-Ⅰ水平低于对照组［（22.01±2.08）μg/L比（26.78±2.63）μg/L］，差异均有统计学意义（t=7.831、11.019，P<0.05）。两组不良反应发生率比较，差异无统计学意义（P>0.05）。结论　加味补阳还五汤联合他克莫司治疗特发性膜性肾病患者效果较好，能有效改善患者脂代谢水平、肾功能、炎症状态及凝血纤溶功能。

关键词:

特发性膜性肾病, 加味补阳还五汤, 他克莫司, 肾功能, 炎症因子

Abstract:

Objective　To explore the efficacy of Jiawei Buyang Huanwu Tang combined with western medicine in the treatment of patients with idiopathic membranous nephropathy. Methods　A total of 120 patients with idiopathic membranous nephropathy treated at Yulin Traditional Chinese Medicine Hospital from September 2020 to September 2023 were selected for the randomized controlled trial, and were divided into a control group and an observation group by the random number table method, with 60 cases in each group. There were 42 males and 18 females in the control group; they were (49.68±5.62) years old. There were 44 males and 16 females in the observation group; they were (49.81±5.54) years old. The control group took tacrolimus, while the observation group took Jiawei Buyang Huanwu Tang and tacrolimus, for 6 months. The clinical efficacies, lipid metabolism levels [total cholesterol (TC), triglycerides (TG), and low-density lipoprotein (LDL)], renal function [24-hour urinary total protein (24 h-UTP), serum creatinine (Scr), and blood urea nitrogen (BUN)], inflammatory markers [transforming growth factor-β1 (TGF-β1), podocyte protein (PCX), and cystatin C (CysC)], and coagulation-fibrinolysis function [tissue plasminogen activator (t-PA) and type Ⅰ plasminogen activator inhibitor [PAI-Ⅰ]) before and after the treatment, and adverse reactions were compared between the two groups. χ² and t tests were used for the statistical analysis. Results　The overall efficacy in the observation group was higher than that in the control group [95.00% (57/60) vs. 80.00% (48/60)], with a statistical difference (χ²=6.171; P<0.05). After the treatment, the levels of TC, TG, LDL, 24 h-UTP, Scr, BUN, TGF-β1, PCX, CysC, t-PA, and PAI-Ⅰ in the observation group were better than those in the control group [(4.31±0.96) mmol/L vs. (6.39±1.24) mmol/L, (1.61±0.46) mmol/L vs. (2.49±0.72) mmol/L, (1.23±0.24) mmol/L vs. (2.59±0.41) mmol/L, (0.56±0.24) g vs. (1.34±0.37) g, (82.57±7.16) μmol/L vs. (88.49±8.64) μmol/L, (6.02±1.03) mmol/L vs. (7.34±1.28) mmol/L, (235.25±14.76) ng/L vs. (301.59±17.64) ng/L, (7.11±1.42) μg/L vs. (12.24±1.78) μg/L, (0.82±0.22) mg/L vs. (1.18±0.34) mg/L, (6.88±1.07) μg/L vs. (5.42±0.97) μg/L, and (22.01±2.08) μg/L vs. (26.78±2.63) μg/L; t=10.274, 7.978, 22.174, 13.700, 4.087, 6.223, 22.341, 17.451, and 6.886, 7.831, and 11.019; all P<0.05]. There was no statistical difference in the incidence rate of adverse reactions between the two groups (P>0.05). Conclusion　Jiawei Buyang Huanwu Tang and tacrolimus in the treatment of patients with idiopathic membranous nephropathy is effective, and can improve their lipid metabolism, renal function, inflammatory status, and coagulation-fibrinolysis function.

Key words:

Idiopathic membranous nephropathy, Jiawei Buyang Huanwu Tang, Tacrolimus, Renal function, Inflammatory markers

鲁小庆郭亚平边静赵东艳景煊峰赵亚峰.

加味补阳还五汤联合西药治疗特发性膜性肾病患者的效果 [J]. 国际医药卫生导报, 2025, 31(4): 573-577.

Lu Xiaoqing, Guo Yaping, Bian Jing, Zhao Dongyan, Jing Xuanfeng, Zhao Yafeng.

Effect of Jiawei Buyang Huanwu Tang combined with western medicine for patients with idiopathic membranous nephropathy [J]. International Medicine and Health Guidance News, 2025, 31(4): 573-577.

参考文献

[1] 王尚飞. 自拟肾病汤对特发性膜性肾病患者肾功能及CysC、TGF-β1、PCX水平的影响[J]. 光明中医,2021,36(13):2192-2194. DOI:10.3969/j.issn.1003-8914.2021. 13.033.
[2] 闫俊慧,张乐,刘育硕,等. 真武汤合肾着汤加减治疗特发性膜性肾病合并急性肾损伤临床观察[J]. 中国中医急症,2024,33(5):852-856. DOI:10.3969/j.issn.1004- 745X. 2024.05.024.
[3] 回妍. 他克莫司联合肾炎康复片治疗特发性膜性肾病的临床研究[J]. 内蒙古医科大学学报,2022,44(5):538-540.
[4] 丁晓宇,王曾,潘智蕙,等. 基于"风、湿、瘀"理论探讨陈洪宇教授治疗特发性膜性肾病经验[J]. 浙江中医药大学学报,2022,46(10):1128-1132. DOI:10.16466/j.issn1005-5509. 2022.10.013.
[5] 殷佳珍,朱彩凤,包自阳,等. 朱彩凤教授加味补阳还五汤治疗特发性膜性肾病经验撷英[J]. 中华中医药学刊,2022,40(8):176-178. DOI:10.13193/j.issn.1673-7717. 2022.08.041.
[6] 于澈,王荣. 特发性膜性肾病诊疗指南解读[J]. 临床内科杂志,2015,32(8):575-576. DOI:10.3969/j.issn.1001-9057. 2015.08.026.
[7] 杨佳,席哲帆,邹皓珍,等. 新型免疫抑制剂在特发性膜性肾病治疗中的研究进展[J]. 国际医药卫生导报,2023,29(18):2517-2521. DOI:10.3760/cma.j.issn.1007-1245.2023. 18.001.
[8] 吴宝利,李宁,张宇,等. 藤草胜湿汤治疗中危特发性膜性肾病的疗效及对血脂、血液流变学的影响[J]. 河北中医药学报,2021,36(3):39-42.
[9] 多慧玲,魏华娟,梁燕,等. "健脾利湿通络方"联合西药治疗脾虚肾络瘀阻型特发性膜性肾病36例临床研究[J]. 江苏中医药,2020,52(8):27-30. DOI:10.19844/j.cnki.1672- 397X. 2020.08.010.
[10] 汤文丽,马放,占永立. 占永立教授益气温阳、活血利水法治疗特发性膜性肾病的经验[J]. 世界中医药,2020,15(18):2785-2789. DOI:10.3969/j.issn.1673-7202.2020.18.023.
[11] 胡宁宁,张丹,邹军,等. 单用他克莫司治疗特发性膜性肾病的效果及安全性评估[J]. 上海交通大学学报(医学版),2022,42(12):1685-1692. DOI:10.3969/j.issn. 1674-8115.2022.12.005.
[12] 邱波,袁良东,李洋,等. 小剂量糖皮质激素联合他克莫司治疗特发性膜性肾病临床疗效与血清抗PLA2R抗体的关系[J]. 实用药物与临床,2022,25(12):1090-1093. DOI:10.14053/j.cnki.ppcr.202212007.
[13] 赵忭阶,李胜开. 环磷酰胺、他克莫司分别与糖皮质激素联合应用治疗特发性膜性肾病的疗效对比观察[J]. 山东医药,2021,61(15):61-64. DOI:10.3969/j.issn.1002- 266X. 2021.15.015.
[14] 刘艳石,任花,黄金娟,等. 雷公藤联合他克莫司治疗特发性膜性肾病的Meta分析[J]. 吉林医学,2023,44(12):3513-3517. DOI:10.3969/j.issn.1004-0412.2023.12.054.
[15] 雷帅兵. 他克莫司联合黄芪赤风汤治疗老年特发性膜性肾病[J]. 河南医学研究,2020,29(3):476-477. DOI:10.3969/j.issn.1004-437X.2020.03.042.
[16] 郎睿,王新慧,闫蕾,等. 健脾祛湿和络方治疗特发性膜性肾病内涵探讨[J]. 山东中医杂志,2024,43(5):466-470. DOI:10.16295/j.cnki.0257-358x.2024.05.006.
[17] 严群,王芳,王法财. 他克莫司与环磷酰胺分别联合激素治疗特发性膜性肾病效果观察[J]. 临床军医杂志,2024,52(7):740-743. DOI:10.16680/j.1671-3826.2024.07.22.
[18] 夏林,黄秋萍,曹秋夏,等. 他克莫司联合糖皮质激素治疗特发性膜性肾病的疗效及对血清PLA2R抗体、Kim-1水平的影响[J]. 临床和实验医学杂志,2023,22(2):158-161. DOI:10.3969/j.issn.1671-4695.2023.02.014.
[19] 仝宗刚,杨乐,赵亚洲. 活瘀祛浊益气方联合泼尼松+他克莫司对特发性膜性肾病患者血清抗PLA2R抗体及氧化应激指标的影响[J]. 海南医学,2023,34(22):3236-3239. DOI:10.3969/j.issn.1003-6350.2023.22.010.
[20] 李婧,李爱仙. 补阳还五汤合参芪地黄汤化裁对糖尿病肾病患者氧化应激与血管内皮功能的影响[J]. 现代中西医结合杂志,2023,32(18):2591-2594. DOI:10.3969/j.issn. 1008-8849.2023.18.021.
[21] 梁小雨. 补阳还五汤辨治特发性膜性肾病探析[J]. 山东中医杂志,2021,40(11):1198-1202. DOI:10.16295/j.cnki. 0257-358x.2021.11.006.
[22] 滕嘉嘉,王志萍,张颖,等. 温阳培土汤对特发性膜性肾病血清白蛋白、BNP、内皮素1影响的临床研究[J]. 中国中西医结合肾病杂志,2023,24(5):405-407. DOI:10.3969/j.issn. 1009-587X.2023.05.011.
[23] 刘学永,王聪舟,李静华,等. 肾炎康胶囊联合化痰袪瘀汤治疗特发性膜性肾病的临床观察[J]. 医学综述,2020,26(13):2693-2697. DOI:10.3969/j.issn.1006-2084.2020.13.037.
[24] 高玉伟,王兴华,杨洪娟,等. 补中益气汤合桂枝汤加减治疗特发性膜性肾病临床观察[J]. 中国中西医结合肾病杂志,2020,21(4):343-345. DOI:10.3969/j.issn.1009- 587X. 2020.04.018.
[25] 赵崇霞,刘旭琴,郭亚平,等. 加味补阳还五汤联合他克莫司治疗气虚血瘀型特发性膜性肾病的效果及对凝血纤溶功能、PLA2R、THSD7A水平的影响[J]. 临床医学研究与实践,2022,7(26):114-117. DOI:10.19347/j.cnki.2096-1413. 202226031.